No longitudinal association between hearing loss and Alzheimer’s disease pathology - 20/01/26
Bienvenue sur EM-consulte, la référence des professionnels de santé.
Article gratuit.
Connectez-vous pour en bénéficier!
Highlights |
• | Baseline hearing loss (HL) was not linked to longitudinal changes in p-tau217. |
• | Baseline HL was not associated with incident amyloid PET positivity. |
• | HL progression did not predict PET outcomes. |
• | APOE4 carriership did not modify associations with Aβ PET. |
• | Baseline plasma biomarkers were also unrelated to longitudinal HL changes. |
Abstract |
Introduction |
Hearing loss (HL) is a potential risk factor for Alzheimer’s disease (AD), with animal studies suggesting a bidirectional relationship. This study examines whether HL links to changes in AD pathology and, whether AD biomarkers relate to subsequent HL progression.
Methods |
Baseline Aβ42/Aβ40 and p-tau217 were measured using single-molecule arrays in 474 participants of the Rotterdam Study (mean age=62.37) between 2010-2016. HL was defined as the better-ear’s pure-tone threshold average. After seven years, participants underwent amyloid PET; HL and p-tau217 were reassessed two years after PET.
Results |
Baseline HL was not associated with amyloid PET positivity, Aβ42/Aβ40, or longitudinally with p-tau217. Likewise, HL progression did not predict PET outcomes. APOE4 carriership did not modify associations with Aβ PET. Similarly, baseline plasma biomarkers were also unrelated to longitudinal HL changes.
Conclusion |
No bidirectional association was observed between HL and AD pathology, suggesting that HL may contribute to dementia through other pathways.
Le texte complet de cet article est disponible en PDF.Keywords : Amyloid PET, Plasma biomarkers, Hearing loss, Longitudinal, Alzheimer’s disease, Risk factor
Plan
Vol 13 - N° 3
Article 100481- mars 2026 Retour au numéro
Article précédent
- Clinical, imaging and blood biomarker outcomes in a Phase 3 clinical trial of tau aggregation inhibitor hydromethylthionine mesylate in mild cognitive impairment and mild to moderate dementia due to Alzheimer’s disease
- Claude M Wischik, Richard Stefanacci, Peter Bentham, Serge Gauthier, Henrik Zetterberg, Gordon K Wilcock, Lutz Froelich, Alistair Burns, Emer MacSweeney, Clive Ballard, Jin-Tai Yu, Tay Siew Choon, Vahe Asvatourian, Natalia Muehlemann, Jan Priel, Karin Kook, Tenecia Sullivan, Diane Downie, Sonya Miller, Carol Pringle, John M. D Storey, Tom Baddeley, Charles R Harrington, Lewis K Penny, Mohammad Arastoo, Roger Staff, Anca-Larisa Sandu, Helen Shiells, Serena Lo, Nafeesa Nazlee, Emily Evans, Claire Hull, Bjoern O Schelter
- The influence of bapineuzumab and semagacestat on rapid progressors: A retrospective cohort study
- Kristofer Harris, Madison Shyer, Dulin Wang, Elizabeth He, Matias Cattani, Catherine Zhang, Christine M. Farrell, Xiaoqian Jiang, Yejin Kim, Paul E. Schulz
Bienvenue sur EM-consulte, la référence des professionnels de santé.